Tirofiban for the treatment of ischaemic stroke

Simone C Bukow1, Michael Daffertshofer, Michael G Hennerici

  • 1Department of Neurology, Universitätsklinikum Mannheim, University of Heidelberg, Germany.

Insights

Tirofiban, a glycoprotein IIb/IIIa antagonist, shows promise for acute ischemic stroke treatment. While experimental data is limited, observational studies suggest potential benefits, warranting further investigation.

Area of Science:

  • Cardiology
  • Neurology
  • Pharmacology

Background:

  • Tirofiban is an FDA-approved glycoprotein IIb/IIIa receptor antagonist.
  • Its current indications include myocardial infarction, unstable angina, and percutaneous coronary intervention for moderate-to-high-risk patients.
  • The efficacy of similar agents in myocardial infarction suggests potential utility in acute ischemic stroke.

Purpose of the Study:

  • To explore the potential of tirofiban in treating acute ischemic stroke.
  • To review existing evidence and identify research gaps regarding tirofiban for stroke.

Main Methods:

  • Review of existing literature on glycoprotein IIb/IIIa antagonists, focusing on tirofiban.
  • Analysis of observational studies and available trial data (one Phase II trial).

Main Results:

  • Observational studies indicate promising outcomes for tirofiban in acute ischemic stroke.
  • Limited experimental data exists, but the mechanism of action suggests potential benefit.
  • Research has predominantly focused on abciximab, with less emphasis on tirofiban.

Conclusions:

  • Tirofiban presents a potential therapeutic option for acute ischemic stroke.
  • Further experimental and clinical trials are needed to establish its efficacy and safety in stroke patients.
  • The findings highlight the need for increased research into tirofiban for neurological applications.

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...